Lifeline Biotechnologies Inc.

(Public, PINK:LLBO)

With the recent gains in Hard to Treat Diseases Inc. (PINK:HTDS) and BioElectronics Corp. (OTC:BIEL), investors were left hungry for more undervalued, high potential biotech companies — Then came LifeLine Biotechnologies Inc (OTC:LLBO). As technology continues to redefine the modern era of medical advancements, certain companies will stand apart from the rest, as is the case with Lifeline Biotechnologies Inc. This company is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. Recently, the company has made headlines with their innovative Breast Cancer detection system, the First Warning System ™, a dynamic test which collects information over time with an uncanny efficacy. The next several months will prove to be critical for LifeLine Biotechnologies, as they await the FDA’s decision

Neoprobe Corporation, a Dublin, Ohio based developer of surgical and diagnostic devices and pharmaceuticals, said today that the European Medicines Agency (EMEA) has approved Neoprobe’s RIGScan® CR cancer detection system for additional testing and development, leading to the potential approval for Neoprobe to market the product throughout the European Union (EU) and affiliated countries.

The EMEA controls the introduction, development, and marketing of medical devices and products in the EU. Neoprobe’s concept for the RIGScan® CR system is a combination of radiation-emitting antibodies with a detection device to assist surgeons in the discovery of tumor deposits that may not be observable by conventional methods.

The company believes it has gotten tangible guidance from the EMEA on how to best continue the design of RIGScan® CR. Furthermore, the EMEA allowed for early termination of additional testing depending on the results. “We are excited by the response